RBS 2418
Alternative Names: RBS-2418Latest Information Update: 11 Jul 2024
At a glance
- Originator Riboscience
- Class Antineoplastics; Small molecules
- Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Clinical Phase Unknown Pancreatic cancer
Most Recent Events
- 31 May 2024 Efficacy, pharmacokinetics and safety data from a phase I trial in Solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 05 Apr 2024 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 20 Oct 2023 Pharmacokinetics, pharmacodynamics, efficacy and adverse events data from a phase I trial in Solid tumours released by Riboscience